Lomond Therapeutics gets FDA clearance for lonitoclax Phase 1 AML study

Lomond Therapeutics Holdings, Inc.

FDA cleared IND for Phase 1 study of lonitoclax in relapsed/refractory acute myeloid leukemia (AML).
Lonitoclax is a selective BCL2 inhibitor with limited immune suppression vs venetoclax.
Phase 1 will evaluate feasibility, safety, tolerability, and efficacy in AML patients.
This is the third U.S. IND clearance for Lomond Therapeutics, marking a key milestone.
CEO Iain Dukes highlighted the advancement of clinical development for lonitoclax.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.